ArticleFrontiers in oncology2025

Case Report: Dual resistance to dasatinib/olverembatinib in accelerated-phase cml: identification of a novel

Jingjing Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.